인공 장기 은행 시장 : 장기 유형, 기술, 소재 유형, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Artificial Organ Bank Market is projected to grow by USD 19.92 billion at a CAGR of 7.25% by 2032.

Artificial Organ Bank Executive Summary

An artificial organ bank is emerging as a strategic healthcare infrastructure model that connects artificial organs, bioartificial organs, implantable devices, engineered tissues, organ preservation systems, and digital matching platforms into a more reliable transplant and organ replacement pathway. Demand is grounded in a measurable public health gap: the U.S. Health Resources & Services Administration reports more than 100,000 people on the national transplant waiting list and about 17 deaths each day while waiting for an organ. Similar pressures are amplified globally by aging populations, diabetes, cardiovascular disease, liver disease, respiratory failure, and chronic kidney disease.

The opportunity is not limited to one device category. It spans total artificial hearts, ventricular assist devices, artificial kidney concepts, artificial pancreas systems, bioengineered grafts, regenerative medicine, 3D bioprinting, xenotransplantation research, cryopreservation, machine perfusion, and AI-enabled logistics. As transplant systems move from scarcity management toward precision allocation and manufactured organ substitutes, the artificial organ bank becomes a core platform for resilience, equity, and clinical continuity.

Transformative Shifts in the Artificial Organ Bank Landscape

The artificial organ bank landscape is shifting from experimental innovation to integrated clinical infrastructure. Advances in biomaterials, decellularized scaffolds, stem-cell-derived tissues, organ-on-chip validation, immunomodulation, and additive manufacturing are accelerating the movement from passive storage toward living, monitored, and quality-controlled organ replacement ecosystems. At the same time, hypothermic and normothermic machine perfusion are extending assessment windows for donor organs and shaping quality protocols that are directly relevant to future artificial and bioartificial organ inventories.

Regulation is also reshaping commercialization. The U.S. FDA, European Medicines Agency, EU Medical Device Regulation, and national health technology assessment bodies increasingly require strong evidence on safety, durability, biocompatibility, cybersecurity, sterility assurance, and real-world performance. This raises development complexity but improves clinical credibility, creating an advantage for organizations that combine clinical validation, traceable supply chains, interoperable data systems, and post-market evidence generation.

Cumulative Impact of Artificial Intelligence on Artificial Organ Banking

Artificial intelligence is becoming a cumulative force across artificial organ banking by improving patient-device matching, transplant prioritization, inventory planning, post-implant monitoring, quality assurance, and adverse-event detection. The FDA has authorized hundreds of AI-enabled medical devices across healthcare, demonstrating regulatory momentum for software-driven clinical decision support, although artificial organ applications still require rigorous validation, bias monitoring, cybersecurity controls, and human clinical oversight.

In practice, AI can help integrate imaging, blood type, HLA data, comorbidity profiles, device performance telemetry, preservation metrics, infection-risk indicators, and logistics constraints into more precise allocation and maintenance decisions. The highest-value use cases are not replacing clinicians but reducing avoidable delays, flagging device deterioration, predicting demand by geography, supporting digital twins for personalized organ replacement planning, and strengthening long-term surveillance after implantation.

Key Regional Insights for Artificial Organ Bank Adoption

Asia-Pacific is gaining momentum through large patient populations, rising chronic disease prevalence, expanding transplant centers, and government support for biotechnology in China, Japan, India, South Korea, Australia, and ASEAN economies. The region is also supported by strong electronics, robotics, biomaterials, and regenerative medicine capabilities, although affordability, reimbursement variation, and access gaps remain important barriers. North America remains the most mature innovation hub because of advanced transplant networks, established organ procurement systems, FDA pathways, academic medical centers, reimbursement depth, and active medtech financing. Europe benefits from coordinated transplant organizations, strong biomedical engineering, established tissue and cell governance, and the EU regulatory push toward traceability, safety, and lifecycle monitoring.

Latin America is led by improving transplant capacity in Brazil, Mexico, Argentina, Chile, and Colombia, but access remains uneven across public and private systems, and specialized infrastructure is concentrated in major cities. The Middle East is investing in specialty hospitals, medical tourism, and national transplant programs, especially across GCC economies, where diabetes, cardiovascular disease, and kidney disease create a strong clinical rationale for advanced organ replacement technologies. Africa continues to face infrastructure, specialist workforce, and affordability constraints, yet selected urban centers in South Africa, Egypt, Kenya, and Nigeria are building clinical capabilities that could support future artificial organ bank partnerships, regional training models, and referral-based implant programs.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN presents an important access opportunity as Indonesia, Thailand, Malaysia, Singapore, Vietnam, and the Philippines expand specialist care, transplant services, and private hospital networks, though reimbursement diversity and uneven transplant infrastructure require localized entry models. The GCC is positioned for premium artificial organ and advanced implant adoption because of high healthcare spending, diabetes and cardiovascular disease burden, government-led hospital modernization, and growing emphasis on medical self-sufficiency. The European Union offers scale through harmonized safety expectations, MDR compliance, cross-border research funding, tissue and cell governance, and data protection requirements that encourage traceable, evidence-led artificial organ bank models.

BRICS economies provide volume-driven demand, domestic manufacturing ambitions, and significant chronic disease burdens, making them central to future affordability and localization strategies across artificial organs, preservation systems, and bioengineered tissues. G7 countries remain primary centers for clinical trials, reimbursement innovation, regulatory science, transplant research, and advanced device adoption due to mature healthcare infrastructure and strong academic networks. NATO markets overlap with many high-income health systems and create opportunities for resilient medical supply chains, dual-use logistics, emergency preparedness planning, and standardized procurement frameworks for high-acuity organ replacement technologies.

Key Country Insights for Artificial Organ Bank Market Prioritization

The United States anchors demand with the world's most visible transplant waiting list data, a mature FDA framework, advanced organ procurement networks, and strong adoption of cardiac support, renal support, and diabetes management technologies. Canada emphasizes regulated access, public reimbursement discipline, and specialized transplant centers, while Mexico and Brazil show rising need supported by expanding hospital capacity and chronic disease management programs; Brazil is particularly important because of its large public transplant system and established national organ donation framework. In Latin America, these country-level dynamics point to a pathway where artificial organ bank adoption is likely to begin in advanced tertiary hospitals before expanding through public-private referral networks.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical expertise with rigorous evidence requirements, established transplant networks, and strong medical technology assessment processes, while Spain is globally recognized for organ donation system performance. Russia maintains scientific and clinical capacity but faces procurement, technology access, and geopolitical constraints that can affect advanced implant availability. China and India represent the largest long-term volume opportunities due to population scale, chronic kidney disease, diabetes, cardiovascular disease, and expanding specialty hospital infrastructure, while Japan, South Korea, and Australia offer sophisticated regulatory systems, robotics, regenerative medicine expertise, and high-quality hospital infrastructure for premium artificial organ bank solutions.

Actionable Recommendations for Artificial Organ Bank Leaders

Industry leaders should prioritize clinically validated product portfolios that combine artificial organs, preservation platforms, digital registries, and AI-enabled monitoring rather than standalone devices. Commercial success will depend on proof of survival benefit, quality-of-life improvement, biocompatibility, infection control, device longevity, equitable access, and total cost-of-care reduction.

Organizations should invest early in regulatory strategy, post-market surveillance, cybersecurity, interoperable data architecture, and evidence generation aligned with transplant workflow. Partnerships with transplant centers, payers, tissue banks, bioprinting labs, public health agencies, and logistics providers can accelerate adoption, while regional manufacturing and service hubs can reduce supply risk for high-acuity implants, preservation systems, consumables, and device maintenance.

Research Methodology for Evidence-Based Market Intelligence

This executive summary is developed using a structured secondary research methodology that triangulates public data from health authorities, transplant registries, regulatory agencies, peer-reviewed journals, clinical trial repositories, patent activity, public disclosures, and recognized global health sources. Core reference inputs include HRSA/OPTN, WHO-linked transplant observatories, FDA device databases, EMA and EU regulatory publications, NIH resources, OECD health indicators, and national transplant agencies.

The analysis evaluates demand drivers, technology readiness, clinical adoption barriers, regulatory context, reimbursement feasibility, regional infrastructure, supply chain resilience, and competitive positioning. Insights are validated through cross-source comparison, exclusion of unsupported claims, and emphasis on evidence-based trends rather than speculative market sizing, market share, or forecasting.

Conclusion: Artificial Organ Banks as Next-Generation Healthcare Infrastructure

The artificial organ bank market is moving toward a platform-based future where engineered organs, advanced preservation, AI-enabled matching, and real-world performance data work together to reduce transplant scarcity. The strongest pathways will come from clinically credible technologies that solve measurable capacity gaps while meeting strict safety, durability, cybersecurity, and reimbursement standards.

Organizations that align innovation with transplant workflow, regional access needs, and long-term patient monitoring will be best positioned to lead. As healthcare systems seek alternatives to organ shortages, artificial organ banks can become a defining infrastructure layer for next-generation replacement medicine and a critical bridge between transplantation, regenerative medicine, and intelligent medical device ecosystems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Artificial Organ Bank Market, by Organ Type

• 7.1. Heart
• 7.2. Intestine
• 7.3. Kidney
• 7.4. Liver
• 7.5. Lung
• 7.6. Pancreas

8. Artificial Organ Bank Market, by Technology

• 8.1. 3D Bioprinting
  • 8.1.1. Extrusion Bioprinting
  • 8.1.2. Inkjet Bioprinting
  • 8.1.3. Laser Assisted Bioprinting
• 8.2. Cell Culture
• 8.3. Decellularization
• 8.4. Scaffold Based Technology
  • 8.4.1. Ceramic Scaffold
  • 8.4.2. Natural Polymer Scaffold
  • 8.4.3. Synthetic Polymer Scaffold

9. Artificial Organ Bank Market, by Material Type

• 9.1. Biological
  • 9.1.1. Allogenic
  • 9.1.2. Autologous
• 9.2. Synthetic
  • 9.2.1. Composite
  • 9.2.2. Polymer

10. Artificial Organ Bank Market, by Application

• 10.1. Pharmaceutical Testing
• 10.2. Research
• 10.3. Transplantation

11. Artificial Organ Bank Market, by End User

• 11.1. Hospitals
• 11.2. Organ Transplant Centers
• 11.3. Research Institutes

12. Artificial Organ Bank Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Artificial Organ Bank Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Artificial Organ Bank Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abiomed, Inc.
• 16.2. Artivion, Inc.
• 16.3. Asahi Kasei Medical Co., Ltd.
• 16.4. B. Braun Melsungen AG
• 16.5. Baxter International Inc.
• 16.6. Berlin Heart GmbH
• 16.7. BiVACOR Pty Ltd
• 16.8. Boston Scientific Corporation
• 16.9. CARMAT SA
• 16.10. CELLINK AB
• 16.11. Cochlear Limited
• 16.12. CryoLife, Inc.
• 16.13. Edwards Lifesciences Corporation
• 16.14. Fresenius Medical Care AG & Co. KGaA
• 16.15. Getinge AB
• 16.16. Jarvik Heart, Inc.
• 16.17. LivaNova PLC
• 16.18. Medtronic plc
• 16.19. Miromatrix Medical Inc.
• 16.20. Nipro Corporation
• 16.21. Organovo Holdings, Inc.
• 16.22. OrganOx Limited by Terumo Corporation
• 16.23. SynCardia Systems, LLC
• 16.24. TransMedics, Inc.
• 16.25. Xvivo Perfusion AB
• 16.26. Zimmer Biomet Holdings Inc.